MedTrace Logo

Pharmacogenetic Study of Mirtazapine Response in Depressed Patients

NCT01039740 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-12-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether pharmacogenetic study predict Mirtazapine responsiveness in advance before the appearance of the drug effect until 4-6 weeks after administration of Mirtazapine.

Conditions

Interventions

DRUG

Mirtazapine

Mirtazapine administration for 6 weeks under therapeutic dose

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Doh Kwan Kim, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039740 on ClinicalTrials.gov